Active Ingredient History
Sotagliflozin, sold under the brand name Zynquista, is a drug approved in the European Union for people with type 1 diabetes. Wikipedia
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Blood Glucose (Phase 3)
Diabetes Mellitus (Phase 2)
Diabetes Mellitus, Type 1 (Phase 3)
Diabetes Mellitus, Type 2 (Phase 3)
Healthy Volunteers (Phase 1)
Heart Failure (Phase 3)
Kidney Failure, Chronic (Phase 1)
Liver Diseases (Phase 1)
Renal Insufficiency, Chronic (Phase 3)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue